Ortho Regenerative Technologies Reports its Second Quarter 2021 Results

  • Closed non-brokered and oversubscribed Private Placements for total gross proceeds of $2.6 million, including $353,000 from management and Board members
  • Preclinical results confirmed safety of Ortho-R and statistical significance over standard of care for rotator cuff repair
  • Ortho-R designated as a Drug/Biologics combination product by the FDA Office for Combination Products
  • Entered into strategic agreement with Ingenew Pharmaceuticals to expand its proprietary biopolymer platform to include the delivery of therapeutics.